Biotech Stocks Post Their Second-Best Month of 2019

  • 11/29/2019
  • Source: Bloomberg
  • by: Tatiana Darie
Biotech Stocks Post Their Second-Best Month of 2019
Biotech stocks are on pace for their second-best month of the year with momentum revived by a return of M&A activity and early FDA approvals for highly anticipated drugs.

The Nasdaq Biotechnology Index rose for its eighth consecutive session on Friday. The benchmark has gained 12% in November, its largest monthly gain since January when the gauge posted its best-ever start to the year. The broader S&P 500 Index has climbed 3.6% since the start of November, while the S&P 500 Health Index has risen about 4.8%.

Industry experts are anticipating more mergers and acquisitions after Novartis AG’s nearly $10 billion deal for Medicines Co, an $85 a share bid which represents a 45% premium to the company’s closing price on Nov. 18.



Oil & gas prices are up. But many O&G stocks have yet to follow. Where should investors look for value opportunities?


Analysis and insights into the newest trends and industries shaping the world and your wealth.

The world is more dynamic than at any time in History.
New Markets are opening up. Technology is accelerating. It’s changing everything.

And creating fortunes in the process.

Dynamic Wealth Research exposes the biggest and most profitable changes for our readers.
© 2016 - 2024 DYNAMIC WEALTH RESEARCH, Privacy Policy, Disclaimer